Addressing these impairments requires a comprehensive management strategy that combines optimal glycemic control (prioritizing medications with potential neuroprotective benefits, such as GLP-1RAs and SGLT2 inhibitors), lifestyle modifications (e.g., aerobic exercise, Mediterranean diet, and cognitive training), and aggressive management of cardiovascular risk factors (hypertension, dyslipidemia). The gene discussed is SLC5A2; the disease is metabolic syndrome.